Prelude Therapeutics Q1 2025 Earnings Report

Prelude Therapeutics EPS Results

• Actual EPS: -$0.42
• Consensus EPS: -$0.47
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: N/A

Prelude Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Prelude Therapeutics Announcement Details

• Quarter: Q1 2025
• Date: 5/6/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 6, 2025
• Conference Call Time: 4:00PM ET

Prelude Therapeutics (NASDAQ:PRLD), Inc. is a clinical-stage precision oncology company dedicated to discovering and developing small molecule therapies that selectively target key vulnerabilities in cancer cells. The company’s research is focused on kinase inhibitors designed to address dysregulated signaling pathways implicated in solid tumors and hematological malignancies. Prelude’s approach leverages structure-based design and translational biomarkers to advance compounds with the potential to improve outcomes for patients with limited treatment options.

Prelude’s pipeline includes several lead drug candidates in various stages of clinical and preclinical development. Among these, PRT2527 is a selective CDK8/19 inhibitor being evaluated for its ability to restore T-cell activity in the tumor microenvironment, while PRT343 targets ALK2 in rare and aggressive forms of soft-tissue sarcoma. The company is also advancing PRT1419, a potent and selective MCL-1 inhibitor, with the aim of inducing apoptotic cell death in hematologic cancers. Each program incorporates companion diagnostics and biomarker strategies to identify patient populations most likely to benefit from therapy.

Headquartered in Cambridge, Massachusetts, Prelude Therapeutics operates a central research facility in the heart of the Boston biotech corridor and collaborates with academic institutions and pharmaceutical partners worldwide. The company’s development efforts extend across the United States and into key international markets, with ongoing discussions to establish strategic alliances for late-stage clinical trials and potential commercialization. Prelude has built a network of research collaborators to enhance translational studies and accelerate timelines for regulatory submissions.

Founded in 2016 by industry veterans with extensive experience in oncology drug discovery and development, Prelude’s leadership team includes professionals who have held senior roles at leading biopharmaceutical companies. Under the guidance of its chief executive officer and chief scientific officer, the company continues to expand its pipeline through both internal discovery programs and external licensing opportunities. Prelude Therapeutics remains committed to advancing innovative therapies that address unmet medical needs in cancer care.